Literature DB >> 15116049

CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences.

Harumi Takahashi1, Grant R Wilkinson, Roberto Padrini, Hirotoshi Echizen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15116049     DOI： 10.1016/j.clpt.2004.01.007

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  10 in total

Review 1.  Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.

Authors:  Mike Ufer
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 2.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  A Bayesian dose-individualization method for warfarin.

Authors:  Daniel F B Wright; Stephen B Duffull
Journal:  Clin Pharmacokinet       Date:  2013-01       Impact factor: 6.447

Review 4.  Pharmacogenetics of oral anticoagulants: a basis for dose individualization.

Authors:  Simone Stehle; Julia Kirchheiner; Andreas Lazar; Uwe Fuhr
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

5.  An acenocoumarol dose algorithm based on a South-Eastern European population.

Authors:  Tudor Radu Pop; Ştefan Cristian Vesa; Adrian Pavel Trifa; Sorin Crişan; Anca Dana Buzoianu
Journal:  Eur J Clin Pharmacol       Date:  2013-06-18       Impact factor: 2.953

6.  Genetic determinants of response to warfarin during initial anticoagulation.

Authors:  Ute I Schwarz; Marylyn D Ritchie; Yuki Bradford; Chun Li; Scott M Dudek; Amy Frye-Anderson; Richard B Kim; Dan M Roden; C Michael Stein
Journal:  N Engl J Med       Date:  2008-03-06       Impact factor: 91.245

7.  Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interaction.

Authors:  Tom Schalekamp; Johanna H H van Geest-Daalderop; Mark H H Kramer; Angelique T M van Holten-Verzantvoort; Anthonius de Boer
Journal:  Eur J Clin Pharmacol       Date:  2007-02-21       Impact factor: 2.953

8.  Evaluation of a pharmacogenetic-based warfarin dosing algorithm in patients with low time in therapeutic range - study protocol for a randomized controlled trial.

Authors:  Leiliane Rodrigues Marcatto; Luciana Sacilotto; Carolina Tosin Bueno; Mirella Facin; Celia Maria Cassaro Strunz; Francisco Carlos Costa Darrieux; Maurício Ibrahim Scanavacca; Jose Eduardo Krieger; Alexandre Costa Pereira; Paulo Caleb Junior Lima Santos
Journal:  BMC Cardiovasc Disord       Date:  2016-11-17       Impact factor: 2.298

9.  An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease.

Authors:  Alberto M Borobia; Rubin Lubomirov; Elena Ramírez; Alicia Lorenzo; Armando Campos; Raul Muñoz-Romo; Carmen Fernández-Capitán; Jesús Frías; Antonio J Carcas
Journal:  PLoS One       Date:  2012-07-20       Impact factor: 3.240

10.  Enzyme Polymorphism in Warfarin Dose Management After Pediatric Cardiac Surgery.

Authors:  Avisa Tabib; Babak Najibi; Mohammad Dalili; Ramin Baghaei; Behzad Poopak
Journal:  Res Cardiovasc Med       Date:  2015-08-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.